Background: So far, there has been no tool to estimate activity at diagnosis and predict all-cause mortality in patients with ANCA-associated vasculitis (AAV). Hence, we determined the initial predictors of them in patients with AAV.
| INTRODUC TI ON
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of three systemic vasculitides involving small vessels, such as microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) according to the 2012 Chapel Hill Consensus Conferences Nomenclature of Vasculitis (the 2012 CHCC definitions). 1 On the basis of small-vessel necrotizing vasculitis, MPA mainly provokes necrotizing glomerulonephritis and pulmonary capillaritis and GPA often causes granuloma formation of the upper and lower respiratory tracts and occasionally necrotizing glomerulonephritis.
Meanwhile, EGPA is characterized by three typical allergic components including asthma, peripheral eosinophilia, and eosinophil-rich granuloma of the respiratory tracts. 1, 2 A natural history of AAV was previously reported. The first-
year and the second-year mortality rates were 82% and 90%, and the main etiology of mortality was uremia as a result of rapidly progressive glomerulonephritis. 3 As various therapeutic regimens were developed and widely used, the first-year mortality rate was remarkably decreased to <10%-20%. 4, 5 Nevertheless, any delayed initiation of induction therapy for severe AAV potentially causes irreversible organ damages, which is eventually jeopardizing the quality of life. Therefore, the early diagnosis and treatment for AAV are required and the proper selection of therapeutic regimens should be carefully chosen based on the stage of the disease and its severity.
Furthermore, the first treatment should be targeted for induction of remission. 2 Birmingham Vasculitis Activity Score (BVAS) has been used for assessing the activity and severity of AAV, and it was reportedly associated with the poor prognosis of AAV. 6, 7 Five-factor score (FFS;
2009) was also used to predict the poor prognosis. 8 Besides BVAS and FFS (2009), several other indices have been applied to Korean patients with AAV, in order to estimate AAV activity at diagnosis and predict the poor prognosis. However, there has been no tool to estimate AAV activity at diagnosis and predict all-cause mortality in patients with AAV, and thus, there has been a great need for a new AAV-specific index for assessing the cross-sectional activity at diagnosis and predicting the prognosis during follow-up in patients with AAV. To elucidate these issues, in this study, we screened variables at diagnosis which were associated with severe AAV and determined the initial predictors of the cross-sectional activity at diagnosis and all-cause mortality during follow-up in immunosuppressive drugnaïve patients with AAV.
| MATERIAL S AND ME THODS

| Patients
We retrospectively screened the medical records of 209 patients with AAV and reviewed those of 182 patients with AVV, who met the conditions as follows: (a) the first classification as AAV at the Agency algorithm and the 2012 CHCC definitions 1, [9] [10] [11] ; (c) the follow-up duration of at least three months or greater; (d) the welldocumented medical records precise enough to assess calculate BVAS and FFS (2009) 6, 8 ; (e) the presence of the results of perinuclear (P)-ANCA and cytoplasmic (C)-ANCA or myeloperoxidase (MPO)-ANCA and proteinase 3 (PR3)-ANCA at diagnosis 12 ; (f) no other medical conditions at diagnosis to confuse the classification of AAV, which were identified by the 10th revised International Classification of Diseases (ICD-10) 13 ; and (g) no history of immunosuppressive drugs prior to or at diagnosis of AAV, which was verified by the Korean Drug Utilisation Review (DUR) system. This study was approved by the Institutional Review Board (IRB) of Severance Hospital (4-2017-0673), and the patient's written informed consent was waived by the approving IRB, as this was a retrospective study.
| Data at diagnosis of AAV
We obtained age at diagnosis and gender in patients with AAV. We reviewed clinical manifestations and laboratory data at diagnosis and then calculated BVAS and FFS (2009). We collected laboratory results at diagnosis, such as white blood cell, neutrophil, lymphocyte and platelet counts, hemoglobin, prothrombin time (international normalized ratio, INR), fasting glucose, blood urea nitrogen, creatinine, total protein, serum albumin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
| Data during follow-up
We defined the follow-up duration as the period from diagnosis to the last visit for patients with remission and/or survived patients, and we defined it as the period from diagnosis to death for deceased patients. Since chronic kidney disease, end-stage renal disease, ischemic heart disease, congestive heart failure, interstitial lung disease, and cerebrovascular disease belong to items of BVAS, we also counted the number of patients with diabetes mellitus and hypertension among comorbidities. We reviewed the administration of immunosuppressive drugs during follow-ups such as glucocorticoid, cyclophosphamide, azathioprine, rituximab, methotrexate, mycophenolate mofetil, and tacrolimus. Death was defined as all-cause mortality.
| Severe AAV
We stratified patients with AAV into three groups based on the tertile of BVAS and defined the lower limit of the highest tertile as the cutoff for the current severe AAV (BVAS at diagnosis ≥16).
| Statistical analyses
All statistical analyses were conducted using SPSS software (version 23 for Windows; IBM Corp). Continuous variables were expressed as a median (interquartile range, IQR), and categorical variables were expressed as number and the percentage. Significant differences in categorical variables between the two groups were analyzed using chi-square and Fisher's exact tests. Significant differences in continuous variables between the two groups were compared using the Mann-Whitney test. The optimal cutoffs of laboratory variables at diagnosis for severe AAV were extrapolated by calculating the area under the receiver operator characteristic curve (AUROC) and selecting the point to maximize the sum of sensitivity and specificity.
The odds ratio (OR) was assessed using the multivariable logistic regression analysis of variables with P values <.05 on the univariable logistic regression analysis. The relative risk (RR) of the optimal cutoff was analyzed using contingency tables and the chi-square test.
Comparison of cumulative patient survival between the two groups was analyzed by the Kaplan-Meier survival analysis. In this study, P values less than 0.05 were considered statistically significant.
| RE SULTS
| Baseline characteristics of patients with AAV
Demographic, clinical, and laboratory data at diagnosis of AAV were described in Table 1 . The most common clinical manifestation at diagnosis was renal involvement (58.2%), followed by pulmonary involvement (56.0%). The median BVAS and FFS (2009) at diagnosis were 12.0 (11.0) and 1.0 (1.0), respectively. The median values of laboratory results were shown in Table 1 . During the follow-up of the median duration of 39.5 (72.0) months, 36 patients (19.8%) had diabetes mellitus and 76 patients (41.8%) had hypertension. The most frequently administered immunosuppressive drug was glucocorticoid (86.8%), followed by cyclophosphamide (41.8%) and azathioprine (53.3%). Fifteen patients (8.2%) died of all etiologies during follow-up (Table 1 ).
| Comparison of laboratory variables at diagnosis between AAV patients with and without severe AAV
Sixty-three patients had BVAS more than 16 and were classified as severe AAV. There were no differences in age and gender between the two groups. Because clinical manifestations at diagnosis were based on all items of BVAS, as was expected, patients with BVAS at diagnosis ≥16 exhibited the higher frequencies of renal, pulmonary, general, cardiovascular, and gastrointestinal manifestations than those without. Compared with non-severe AAV patients, patients with severe AAV had the increased median neutrophil count, platelet count, blood urea nitrogen, creatinine, ESR, and CRP than those without. On the other hands, patients with severe AAV exhibited the lower median lymphocyte count, hemoglobin, and serum albumin than those without ( Table 2) . As there was collinearity between blood urea nitrogen and creatinine, we excluded it in the following analyses.
| Optimal cutoffs of laboratory variables for severe AAV at diagnosis
We obtained the optimal cutoffs of laboratory variables at diagnosis for severe AAV, which were significant in the comparative analysis between patients with and without severe AAV. (Table   S1 ). Although platelet count exhibited no statistical significance (area 0.568, 95% confidence interval (CI) 0.475, 0.661), we included platelet count ≥ 352 500.0/mm 3 in the logistic regression analyses, because it significantly differed between patients with and without severe AAV in the comparison analysis.
| Univariable and multivariable logistic regression analyses for severe AAV at diagnosis
Since there were no significant differences in age at diagnosis and gender between the two groups, we did not include them in the Table 3 ). In the multivariable logistic regression analysis of laboratory variables at diagnosis for severe AAV, only creatinine ≥ 0.9 mg/dL was significantly associated with severe AAV at diagnosis (OR 2.264, 95% CI 1.107, 5.040). In addition, lymphocyte count ≤ 1430.0/mm 3 and hemoglobin ≤ 10.8 g/ dL also tended to be associated with severe AAV at diagnosis (OR 1.856, 95% CI 0.906, 3.804 and OR 2.085, 95% CI 0.917, 4.737, respectively; Table 3 ). We derived an equation of a multivariable index for AAV (MVIA) using lymphocyte count, hemoglobin, and creatinine with P value < .01 in the multivariable logistic regression analysis.
| Equation of MVIA
We assigned a weight of a number close to an integer to each 
| Optimal cutoff of MVIA for severe AAV
The median calculated MVIA was 0.8 with IQR of 1.5. The maximum and minimum MVIA were 2.1 and 0, respectively. MVIA was positively correlated with BVAS at diagnosis (r = 0.370, P < .001). We also obtained the optimal cutoff of MVIA for severe AAV as 1.35 (sensitivity 0.667 and specificity 0.689) using the AUROC curve (area 0.727, 95% CI 0.648, 0.805; Figure 1A ). When we divided patients with AAV into the two groups based on the optimal cutoff of MVIA for severe AAV, 79 patients belonged to the group of MVIA at diagnosis ≥1.35.
The cross-sectional severe AAV appeared more frequently in patients with MVIA at diagnosis ≥1.35 than those without (53.2% vs 20.4%, P < .001). In addition, patients with MVIA at diagnosis ≥1.35 exhibited a significantly high RR for severe AAV at diagnosis, compared to those without (RR 4.432, 95% CI 2.309, 8.507; Figure 1B ).
| Cumulative patient survival rate
We investigated the cumulative patient survival rate during followup between patients with and without MVIA at diagnosis ≥1.35. 
TA B L E 1 (Continued)
Patients with MVIA at diagnosis ≥1.35 exhibited the lower cumulative patient survival rate than those with MVIA <1.35 (P = .006). We also applied the Kaplan-Meier survival analysis to all laboratory variables having optimal cutoffs and found only hemoglobin at diagnosis ≤10.8 g/dL was significantly associated with all-cause mortality in patients with AAV (P = .006; Figure 2 ). count may also be affected by general health and stress or various autoimmune diseases and we previously proved the lower number of lymphocyte in severe AAV compared with non-severe AAV. 15 Second, the reduced hemoglobin was reported to be one of systemic complication of AAV. 16 Third, serum creatinine level is already included in BVAS as one item, and thus, it is naturally accepted that the serum level of creatinine might be correlated with BVAS well. 6 We found that MVIA at diagnosis ≥1. 35 or no = 0) + 1.9 × (Creatinine ≥ 1.16 mg/dL: yes = 1 or no = 0). In addition, we obtained the optimal cutoff of MVIA for FFS at diagnosis ≥2 as 1.75 (sensitivity 0.667 and specificity 0.689) using the AUROC curve (area 0.850; Figure S2 ). We found that MVIA based on FFS at diagnosis ≥1.75 exhibited no significant difference in patient survival rate from MVIA based on FFS at diagnosis <1.75 (P = .072; Figure S3 ). Therefore, we conclude that MVIA based on BVAS at diagnosis ≥1.35 could predict all-cause mortality during follow-up in patients with AAV than MVIA based on FFS at diagnosis ≥1.75.
| D ISCUSS I ON
Our study has several limitations. This study is based on study population that was not large enough to represent the clinical data of all-Korean patients with AAV. Also, due to the retrospective study design, the usefulness of MVIA was not explored for assessing the serially changing the cross-sectional activity and severity of AAV under the administration of immunosuppressive drugs.
However, we hope that future nationwide prospective studies with a larger number of patients with AAV could overcome all of these issues.
Our study has several merits. We have first developed an AAVspecific index for assessing the cross-sectional activity and severity and predicting all-cause mortality in patients with AAV. Because we included patients, who had been classified as AAV at the same department of one tertiary hospital, our study was able to minimize the inter-centric variation. Also, our institute is one of the biggest tertiary university hospitals in Korea, and furthermore, our AAV cohort is the only one in Korea. So, almost all the patients are transferred to our institute when a situation occurs requiring consideration of death in patients with AAV. In addition, we tried to contact patients with AAV, who were not followed up, by phone and so we could precisely confirm all-cause mortality, although the causes of death were not known in all patients. Lastly, given that the clinical features and the prognosis of AAV may vary based on geographical and ethnic differences, this study first demonstrated the clinical implication of MVIA in Korean patients with AAV.
| CON CLUS ION
A new AAV-specific MVIA could assess the cross-sectional activity and severity and predict all-cause mortality in immunosuppressive drug-naïve patients with AAV during follow-up.
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